Fig. 4: Combined olaparib and AZD6738 treatment results in earlier commitment to apoptosis in the absence of ATM. | Oncogene

Fig. 4: Combined olaparib and AZD6738 treatment results in earlier commitment to apoptosis in the absence of ATM.

From: Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Fig. 4

a Cell growth (% confluency) of cells co-stained with activated caspase 3/7 (apoptosis) and Cytotox (cell death) in FaDu ATM-KO and WT cells following olaparib and AZD6738 single-agent and combination treatment. Apoptosis and cell death activity is represented by mean fluorescence levels of caspase 3/7 or cytotox normalised to total cell confluency. % confluency and fluorescence intensities were calculated using incucyte ZOOM 2016A software. 0.1 μM staurosporine was used as a positive control for apoptosis. An independent repeat is shown in Supplementary Fig. 8A. b Schematic indicating in vitro washout dose schedules used in Figs. 4c, 5b and 6b. c Cell growth (% confluency) over 14 days of single and dual olaparib/AZD6738 treatment using the dose schedules outlined in Fig. 4b. Inhibitors were dosed at 0 h and the media replaced after either 3 or 5 days as indicated by the grey dashed line. Error bars = mean ± SEM (n = 3). Two independent biological repeats are shown in Supplementary Fig. 8Bi–ii.

Back to article page